Amgen Change in Accrued Sales Incentives increased by 88.8% to $1.18B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 27.4%, from $929.00M to $1.18B. Over 3 years (FY 2021 to FY 2024), Change in Accrued Sales Incentives shows an upward trend with a 43.5% CAGR.
An increase suggests higher projected rebate obligations, while a decrease indicates that previous incentives have been settled or adjusted.
This metric tracks the change in liabilities related to rebates, discounts, and sales incentives offered to customers, s...
Common in pharmaceutical and biotech industries; peers report this as a key component of revenue recognition and cash flow management.
cf_amgn_change_in_accrued_sales_incentives| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $101.00M | $101.00M | $101.00M | $211.50M | $211.50M | $211.50M | $211.50M | -$402.00M | $575.00M | $242.00M | $520.00M | -$316.00M | -$77.00M | $929.00M | $658.00M | $486.00M | $627.00M | $1.18B |
| QoQ Change | — | +0.0% | +0.0% | +109.4% | +0.0% | +0.0% | +0.0% | -290.1% | +243.0% | -57.9% | +114.9% | -160.8% | +75.6% | >999% | -29.2% | -26.1% | +29.0% | +88.8% |
| YoY Change | — | — | — | — | +109.4% | +109.4% | +109.4% | -290.1% | +171.9% | +14.4% | +145.9% | +21.4% | -113.4% | +283.9% | +26.5% | +253.8% | +914.3% | +27.4% |